GetTopicDetailResponse(id=a6101124117b, topicName=Elacestrant, introduction=Elacestrant, content=Elacestrant ESR1突變 乳腺癌, image=null, comments=0, allHits=733, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Mon Mar 18 13:50:35 CST 2024, time=2024-03-18, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=109697, tagList=[TagDto(tagId=109697, tagName=Elacestrant)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2193871, encodeId=4cfc21938e1c6, content=<a href='/topic/show?id=a6101124117b' target=_blank style='color:#2F92EE;'>#Elacestrant#</a> <a href='/topic/show?id=ed7a112412df' target=_blank style='color:#2F92EE;'>#ESR1突變#</a> <a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, objectTitle=JCO | FDA批準摘要：elacestrant 用于治療ER陽性、HER2陰性、ESR1突變晚期或轉(zhuǎn)移性乳腺癌, objectType=article, longId=817403, objectId=3d2081e40305, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240318/1710737720721_6145188.png, objectUrl=/article/show_article.do?id=3d2081e40305, replyNumber=0, likeNumber=110, createdTime=2024-03-18, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3d2081e40305, moduleTitle=JCO | FDA批準摘要：elacestrant 用于治療ER陽性、HER2陰性、ESR1突變晚期或轉(zhuǎn)移性乳腺癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3d2081e40305)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-03-18發(fā)表于上海
